The coming of age of hadrontherapy


There’s a problem with conventional radiotherapy for tumours: the body absorbs the radiation as it passes through. So zap a deep seated tumour with X-rays and the dose decreases exponentially with the depth of target. This means that both diseased and healthy tissue end up getting targeted.

In 1946, Robert Wilson, a physicist  at FermiLab near Chicago pointed out that protons with an energy of between 200 and 250 MeV and carbon ions with an energy of 3500 to 4500 MeV work in a different way. Inside the body, they tend to dump all their energy at the end of their range. Not only that, but because the particles are charged, they can be sharply focused. He said that makes these particles ideal for targeting tumours.

It’s taken 60 years, but there is now real interest in hadrontherapy. Several thousand patients have been treated at various particle physics labs around the world. and therein lies the problem: the only places that can produce protons or carbon ions with these energies are  specialised accelerators such as those at GSI in Germany and Chiba in Japan.

There is one facility dedicated to medical work at the Loma Linda University Medical Centre near Los Angeles but it has become clear to the medical and physics community that more are desperately needed.

So how do you build reliable, easy-t0-use, affordable particle accelerators for medical centres? Enter Ugo Amaldi and buddies from the TERA Foundation in Italy, who today propose a design that they think could revolutionise this kind of treatment. (Amaldi was a hot shot at the European particle physics lab CERN for many years before turning to medical therapy.)

The idea is to build a cyclotron (a circular accelerator) and bolt it to a linac (a linear accelerator) and to call the hybrid a Cyclinac. So protons or carbon ions are injected into the cyclotron which stores and accelerates them. They are then injected into a linac which accelerates them to the appropriate energies for medical applications. The result is a therapeutic beam ready for action.

This design can also produce synchrotron  x-rays for other  medical apps.
Of course, there several significant engineering challenges ahead, like increasing the repetition rate of these devices to practical levels, something that Cyclinacs are being designed to address.

The big question, of course, is not whether such a project will be funded (everyone seems to agree on that) but when. And then where to build it. Given the Terra Foundation’s location, what odds on Italy being host to the first of these devices in Europe?

Ref: Cyclinacs: Fast-Cycling Accelerators for Hadrontherapy

One Response to “The coming of age of hadrontherapy”

  1. No doubt the perspective is very interesting and it has a good potential to improve the prognosis of people with certain kind of pathologies. The obvious problems are related to finding the right investors, something which in Europe is often not as straightforward as in the US. Moreover, it has to be taken into account the present financial crisis. On top of this, it is not a so-wrong claim that Italy has a political equilibrium with complex mechanisms. The right junctions need oil in order to work properly. Hadrontherapy will certainly face these issues.